SEATTLE, Dec. 21, 2017 — Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions today announced that Carl Novina, MD, PhD, has been appointed as Scientific Advisor.
Dr. Novina is one of the leading researchers in the field of RNAi therapeutics. He is an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. He is currently the Principal Investigator of the Novina Lab at the Dana-Farber Cancer Institute. His laboratory has made several important discoveries into the biology of noncoding RNAs, their dysregulation in cancers, and their development as biomedical tools.Dr. Novina received his M.D. from Columbia University, College of Physicians and Surgeons in 2000 and his Ph.D. from Tufts University, Sackler School of Graduate Biomedical Sciences in 1998. His graduate work has resulted in 10 publications examining transcriptional regulation of TATA-less promoters. In 2014 he received the coveted National Institutes of Health Pioneer Award, which funds bold and innovative research proposals to attack challenging biomedical problems. Dr. Novina has established many collaborations between industry partners and physicians to facilitate his goal of bringing biomedical innovations from bench to bedside.“We are delighted to welcome Dr. Novina to our Scientific Advisory Board which is composed of world-class experts in Breast Cancer research,” said Dr. Steve Quay, President and CEO of Atossa Genetics. “Dr. Novina’s immunology expertise will be invaluable as we develop our proprietary microcatheters for delivery of CAR-T cell therapies for the treatment of the deadlier forms of breast cancer.”About Atossa GeneticsAtossa Genetics Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.Forward-Looking StatementsForward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.Atossa Genetics Company Contact:Atossa Genetics Inc.
CFO and General Counsel
Phone 206 556-3238
[email protected]Investor Relations ContactScott Gordon
377 Oak Street
Garden City, NY 11530
Phone (516) 222-2560
[email protected]Source: Atossa Genetics Inc.
Latest posts by Brad Bennett (see all)
- United States Emergency Ambulance Market by Manufacturers, States, Type and Application, Forecast to 2022; New Report Launched - February 23, 2018
- Scott Lipps's Modeling/Celebrity Agency “Lipps LA” wins the Best of Los Angeles Award for â€œBest Visionary Modeling Agencyâ€� 2018 - February 23, 2018
- Ontario International Airport passenger volume gained over 10% in January, while cargo grew more than 22% - February 23, 2018